|
MechanismFGFR2 antagonists |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
/ Not yet recruitingPhase 1 A First-in-human, Open-label, Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Activity of 3HP-2827 in Patients With Unresectable or Metastatic Solid Tumors With FGFR2 Alterations
The study is being conducted to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of 3HP-2827 in the treatment of unresectable or metastatic solid tumors with FGFR2 alterations. Patients will be enrolled in two stages: dose escalation stage (Stage I) and expansion stage (Stage II).
An Open-Label, Multi-center Phase 1/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Activity of 3HP-2827 in Patients With Unresectable or Metastatic Solid Tumors With FGFR2 Alterations
The study is being conducted to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of 3HP-2827 in the treatment of unresectable or metastatic solid tumors with FGFR2 alterations.
3HP-2827在FGFR2异常的手术不可切除/转移性实体瘤患者中的安全性、耐受性、药代动力学和疗效的开放、多中心1/2期临床研究
[Translation] An open-label, multicenter Phase 1/2 clinical study of the safety, tolerability, pharmacokinetics, and efficacy of 3HP-2827 in patients with surgically unresectable/metastatic solid tumors with FGFR2 abnormalities
评估3HP-2827在FGFR2异常的手术不可切除/转移性实体瘤患者中的安全性、耐受性和疗效
[Translation] To evaluate the safety, tolerability, and efficacy of 3HP-2827 in patients with surgically unresectable/metastatic solid tumors with FGFR2 abnormalities
100 Clinical Results associated with 3H (Suzhou) Pharmaceuticals Co., Ltd
0 Patents (Medical) associated with 3H (Suzhou) Pharmaceuticals Co., Ltd
100 Deals associated with 3H (Suzhou) Pharmaceuticals Co., Ltd
100 Translational Medicine associated with 3H (Suzhou) Pharmaceuticals Co., Ltd